Clinical Trial

Antibacterial Tactics Based on Presepsin Level in Thoracic Aorta Surgery Patients

Recruiting
View on ClinicalTrials.gov →
Summary
According to the literature, presepsin was recommended not only as an effective indicator in the diagnosis of sepsis in intensive care units, but also as a reliable prognostic marker of postoperative inflammatory processes in cardiac surgery. Previous study carried out in Petrovsky NRCS related to biomarkers in cardiac surgery and presepsin in particular showed good sensitivity in infection complications prognosis.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-03-21; most recent amendment 2026-01-28.
Trial Details
NCT Number NCT06336213
Lead Sponsor Petrovsky National Research Centre of Surgery
Conditions Aortic Aneurysm and Dissection, Cardiac Valve Disease, Thoracic Aortic Aneurysm, Thoracic Aortic Dissection
Enrollment 50 participants
Start Date 2024-01-23
Primary Completion 2026-12-15 (estimated)
Study Completion 2027-02-15 (estimated)
Updated on ClinicalTrials.gov 2026-01-29